Applied Genetic Technologies (AGTC) Misses Q3 EPS by 4c

Applied Genetic Technologies (NASDAQ: AGTC) reported Q3 EPS of ($0.45), $0.04 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.57 million.

For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance